PubMed

Pharmacometrics and the transition to model-based development.

Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E.

Clin Pharmacol Ther. 2007 Aug;82(2):137-42. Review.PMID: 17632539 [PubMed - indexed for MEDLINE]Related articles

Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?

Edelman SV, Garg S, Kolterman OG.

Nat Clin Pract Endocrinol Metab. 2007 May;3(5):E1; discussion E2. No abstract available. PMID: 17452962 [PubMed - indexed for MEDLINE]Related articles

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.

Amiel SA, Heller SR, Macdonald IA, Schwartz SL, Klaff LJ, Ruggles JA, Weyer C, Kolterman OG, Maggs DG.

Diabetes Obes Metab. 2005 Sep;7(5):504-16.PMID: 16050943 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C.

Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204.PMID: 15891954 [PubMed - indexed for MEDLINE]Related articles

Properties of pramlintide and insulin upon mixing.

Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF.

Am J Health Syst Pharm. 2005 Apr 15;62(8):816-22.PMID: 15821274 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD.

Am J Health Syst Pharm. 2005 Jan 15;62(2):173-81.PMID: 15700891 [PubMed - indexed for MEDLINE]Related articles

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD.

J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9.PMID: 12843147 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.PMID: 12017421 [PubMed - indexed for MEDLINE]Related articles

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Weyer C, Maggs DG, Young AA, Kolterman OG.

Curr Pharm Des. 2001 Sep;7(14):1353-73. Review. Erratum in: Curr Pharm Des 2001 Dec;7(18):1967. PMID: 11472273 [PubMed - indexed for MEDLINE]Related articles

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.

Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG.

Diabetes Care. 1998 Jun;21(6):987-93.PMID: 9614619 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.

Thompson RG, Pearson L, Kolterman OG.

Diabetologia. 1997 Nov;40(11):1278-85.PMID: 9389419 [PubMed - indexed for MEDLINE]Related articles

Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.

Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG.

Diabet Med. 1997 Jul;14(7):547-55.PMID: 9223392 [PubMed - indexed for MEDLINE]Related articles

Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.

Kolterman OG.

Diabet Med. 1997 Jun;14 Suppl 2:S35-8. Review.PMID: 9212328 [PubMed - indexed for MEDLINE]Related articles

Self-care behaviors in insulin-dependent diabetes: evaluative tools and their associations with glycemic control.

Hanson CL, De Guire MJ, Schinkel AM, Kolterman OG, Goodman JP, Buckingham BA.

J Pediatr Psychol. 1996 Aug;21(4):467-82.PMID: 8863457 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A.

Diabetologia. 1996 Apr;39(4):492-9.PMID: 8778001 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes.

Colburn WA, Gottlieb AB, Koda J, Kolterman OG.

J Clin Pharmacol. 1996 Jan;36(1):13-24.PMID: 8932539 [PubMed - indexed for MEDLINE]Related articles

Empirical validation for a family-centered model of care.

Hanson CL, De Guire MJ, Schinkel AM, Kolterman OG.

Diabetes Care. 1995 Oct;18(10):1347-56.PMID: 8721936 [PubMed - indexed for MEDLINE]Related articles

Low-carbohydrate diet alters intracellular glucose metabolism but not overall glucose disposal in exercise-trained subjects.

Cutler DL, Gray CG, Park SW, Hickman MG, Bell JM, Kolterman OG.

Metabolism. 1995 Oct;44(10):1264-70.PMID: 7476282 [PubMed - indexed for MEDLINE]Related articles

Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.

Kolterman OG, Gottlieb A, Moyses C, Colburn W.

Diabetes Care. 1995 Aug;18(8):1179-82.PMID: 7587855 [PubMed - indexed for MEDLINE]Related articles

Type II diabetes: who has the keys?

Kolterman OG.

J Lab Clin Med. 1993 Apr;121(4):534-5. No abstract available. PMID: 8454933 [PubMed - indexed for MEDLINE]Related articles

Glyburide in non-insulin-dependent diabetes: an update.

Kolterman OG.

Clin Ther. 1992 Mar-Apr;14(2):196-213. Review.PMID: 1611644 [PubMed - indexed for MEDLINE]Related articles

Elevated insulin, norepinephrine, and neuropeptide Y in hypertension.

Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG.

Am J Hypertens. 1990 Nov;3(11):823-8.PMID: 2261148 [PubMed - indexed for MEDLINE]Related articles

Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system.

Garvey WT, Kolterman OG.

Diabetes Metab Rev. 1988 Sep;4(6):543-69. Review. No abstract available. PMID: 3065009 [PubMed - indexed for MEDLINE]Related articles

Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion.

Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG.

Diabetes. 1988 May;37(5):590-9.PMID: 3282946 [PubMed - indexed for MEDLINE]Related articles

Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM.

Wright KS, Beck-Nielsen H, Kolterman OG, Mandarino LJ.

Diabetes. 1988 Apr;37(4):436-40.PMID: 2837418 [PubMed - indexed for MEDLINE]Related articles

Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism.

Mandarino LJ, Wright KS, Verity LS, Nichols J, Bell JM, Kolterman OG, Beck-Nielsen H.

J Clin Invest. 1987 Sep;80(3):655-63.PMID: 2957389 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics.

Baron AD, Eckel RH, Schmeiser L, Kolterman OG.

Metabolism. 1987 May;36(5):409-15.PMID: 3553848 [PubMed - indexed for MEDLINE]Related articles

The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics.

Kolterman OG.

Diabetes Metab Rev. 1987 Apr;3(2):399-414. Review.PMID: 3552528 [PubMed - indexed for MEDLINE]Related articles

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.

Baron AD, Schaeffer L, Shragg P, Kolterman OG.

Diabetes. 1987 Mar;36(3):274-83.PMID: 2879757 [PubMed - indexed for MEDLINE]Related articles

Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic subjects.

Mandarino LJ, Madar Z, Kolterman OG, Bell JM, Olefsky JM.

Am J Physiol. 1986 Oct;251(4 Pt 1):E489-96.PMID: 3094377 [PubMed - indexed for MEDLINE]Related articles

Antiinsulin receptor antibodies in an insulin-dependent diabetic may arise as autoantiidiotypes.

Shoelson SE, Marshall S, Horikoshi H, Kolterman OG, Rubenstein AH, Olefsky JM.

J Clin Endocrinol Metab. 1986 Jul;63(1):56-61.PMID: 3486878 [PubMed - indexed for MEDLINE]Related articles

Metabolic consequence of two-week fructose feeding in diabetic subjects.

Crapo PA, Kolterman OG, Henry RR.

Diabetes Care. 1986 Mar-Apr;9(2):111-9.PMID: 3516605 [PubMed - indexed for MEDLINE]Related articles

In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man.

Glauber HS, Revers RR, Henry R, Schmeiser L, Wallace P, Kolterman OG, Cohen RM, Rubenstein AH, Galloway JA, Frank BH, et al.

Diabetes. 1986 Mar;35(3):311-7.PMID: 3512341 [PubMed - indexed for MEDLINE]Related articles

Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects.

Henry RR, Wiest-Kent TA, Scheaffer L, Kolterman OG, Olefsky JM.

Diabetes. 1986 Feb;35(2):155-64.PMID: 3510922 [PubMed - indexed for MEDLINE]Related articles

Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects.

Baron AD, Kolterman OG, Bell J, Mandarino LJ, Olefsky JM.

J Clin Invest. 1985 Nov;76(5):1782-8.PMID: 2865274 [PubMed - indexed for MEDLINE]Related articlesFree article

Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.

Kolterman OG.

Am J Med. 1985 Sep 20;79(3B):23-33.PMID: 3931459 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes.

Olefsky JM, Ciaraldi TP, Kolterman OG.

Am J Med. 1985 Sep 20;79(3B):12-22.PMID: 3901744 [PubMed - indexed for MEDLINE]Related articles

Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus.

Garvey WT, Revers RR, Kolterman OG, Rubenstein AH, Olefsky JM.

J Clin Endocrinol Metab. 1985 Mar;60(3):559-68.PMID: 3882736 [PubMed - indexed for MEDLINE]Related articles

The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging.

Fink RI, Revers RR, Kolterman OG, Olefsky JM.

Diabetes. 1985 Mar;34(3):275-80.PMID: 3882495 [PubMed - indexed for MEDLINE]Related articles

The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.

Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG.

Diabetes. 1985 Mar;34(3):222-34.PMID: 3882489 [PubMed - indexed for MEDLINE]Related articles

Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus.

Olefsky JM, Revers RR, Prince M, Henry RR, Garvey WT, Scarlett JA, Kolterman OG.

Adv Exp Med Biol. 1985;189:176-205.PMID: 3898763 [PubMed - indexed for MEDLINE]Related articles